Sign Up
Stories
FDA Clears NOX-A12 for Glioblastoma
Share
Advancements in Brain Cancer, TTFields, ...
Advancements in Cancer Treatment and Mar...
Advancements in Clinical Trials
AI-Powered Cancer Drug Trials
Advancing CD70 Targeted Cancer Treatment...
Affini-T Therapeutics at J.P. Morgan Hea...
Overview
API
TME Pharma gains FDA approval for NOX-A12 to treat glioblastoma in Phase 2 trial, eyeing US expansion.
Ask a question
How does the potential success of NOX-A12 in glioblastoma treatment influence other brain cancer research endeavors?
How might the FDA's clearance impact the future landscape of glioblastoma treatment?
What challenges could TME Pharma face in the US market expansion process?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Dec 2023
Jan 2024
Feb 2024
Coverage